Tag: multiparametric MRI

What if knowing everything about your prostate wasn’t just about high-tech scans, but also about someone truly hearing what matters most? Empathic listening and attention to personal values at Sperling Prostate Center set the stage for more informed, satisfying choices in prostate care. keep reading

Can a cancer diagnosis bring a sense of relief? For men with prostate cancer caught at Grade Group 1, emerging research and expert protocols suggest that aggressive treatments can often be avoided. Active surveillance, targeted focal therapies, and more precise diagnostic tools are helping many choose paths that spare quality of life. keep reading

Recent research uncovers substantial agreement between MRI-targeted prostate biopsy results and surgical specimens, offering fresh insight into biopsy accuracy for prostate cancer. Rates of concordance are highest for more aggressive disease, yet lower for lower-grade findings. keep reading

What if treating prostate cancer didn’t have to mean sacrificing the whole gland? Thanks to advances in multiparametric MRI and MRI-targeted biopsy, focal therapy can pinpoint and erase tumors with a margin of safety while sparing healthy tissue. Lower side effect rates and preserved function set this approach apart. keep reading

Research indicates that regular mpMRI scans and PSA density checks might allow some prostate cancer patients on active surveillance to delay confirmatory biopsy at one year. While the evidence is promising, experts say more study is needed before changing established protocols. keep reading

Choosing the right prostate cancer treatment goes beyond medical statistics—it's about aligning therapy with individual lifestyles, priorities, and long-term well-being. Shared decision-making, patient-reported outcomes, and emerging therapies offer hope for better cancer control with fewer side effects. keep reading

Discover how PI-RADS v2.1 has raised the bar for prostate cancer detection, and how the new PI-RR system helps identify recurrence after surgery or radiation. Updated imaging guidelines are making diagnosis and follow-up more reliable. keep reading

Recent long-term data reveal that active surveillance can offer high prostate cancer-specific survival when paired with advanced monitoring tools like multiparametric MRI and biomarkers. Experts emphasize the importance of a proactive, technology-driven approach to achieve the best treatment-free survival. keep reading

UPDATE: 11/21/2025 Originally published Mar. 11, 2024 The blog below announced news that before radical prostatectomy (RP), multiparametric MRI findings can predict if a prostate cancer (PCa) patient is at risk of recurrence after RP. Prior to MRI predictions, the CAPRA-S score had become the gold standard for predicting biochemical recurrence risk—but only after the surgery was done. Thus, keep reading

Australia is rethinking prostate cancer screening, proposing annual PSA testing, earlier screenings for high-risk men, and the integration of mpMRI to improve detection. The reforms aim to address past guideline shortcomings and reduce late-stage diagnoses. keep reading